Thomas Pfeiffer, MD

Looking for a small meeting with leaders in cell therapy discussing high impact translational research? Look no further! The UChicago Jonas Center Symposium is for you! Please get in touch if you're interested or, better yet, register and join us! cme.uchicago.edu/JCCTS2024

WashU Medicine rises to No. 2 in nation in NIH research funding @SitemanCenter @WUDeptMedicine @WUSTLmed medicine.wustl.edu/news/washu-med…

stjude.org/education-trai… 🔬 Excited for the upcoming International Conference on Cellular Immunotherapy in Pediatric Oncology at St. Jude! Hope to see you there! @Kyttaro_Therapy @castillopa5

John DiPersio, MD, PhD, a @WUSTLmed physician-scientist and Siteman research member, received the 2024 E. Donnall Thomas Prize from @ASTCT. It recognizes a physician or scientist who has contributed to advancement in blood and marrow transplantation. siteman.wustl.edu/dipersio-recei…

Join us for The International Conference on Cellular Immunotherapy in Pediatric Oncology (CIPO) at St. Jude in June 2024. stjude.org/education-trai… @StJude @StJudeResearch @ASTCT @ThePTCTC

Todd A. Fehniger, MD, and co-principal investigators Jeffrey J. Bednarski, MD, and Thomas Pfeiffer, MD, all from @WUSTLmed have received a $1.4 million grant from the Rising Tide Foundation for Clinical Cancer Research, @SitemanCenter Kids & @LLSusa Link>l8r.it/eJKn

Preclinical development of CD2-edited CD2 CAR-T for T-cell malignancies. As expected, CD2 deletion reduces T-cell cytotoxicity but supplementation with "long-playing" engineered IL-7 helps sustain responses in vivo @DiPersioLab nature.com/articles/s4137…

Announcing an opening for a Staff Scientist in my lab! Links to all open positions below. Join us to study immune regulation of graft-vs-host disease (#GVHD)! Staff Scientist: wustl.wd1.myworkdayjobs.com/External/job/W… Postdoc: wustl.wd1.myworkdayjobs.com/External/job/W… Research Opportunity: wustl.wd1.myworkdayjobs.com/External/job/W…

Pedal-funded researcher Dr. Jeff Bednarski & team from @SitemanCenter Kids, @STLChildrens & @WUSTLmed were the only ones in the world using a new immune therapy developed to treat leukemia patients. Over 100 kids treated so far! #NationalCancerResearchMonth

Donor-derived CD19 CAR-T in pediatric ALL using two manufacturing strategies: open method+gammaretro vs Prodigy+lenti. Congrats on another excellent study @Fra_delBufalo! ashpublications.org/blood/article/…

Our study of NGS-based MRD in HCT for adult ALL is published! Pre-HCT MRD even at low levels <10-4 and post-HCT MRD predicted relapse. In B-cell ALL, IgH clonotypes, rather than non-IgH, were associated with relapse. (1/3) ashpublications.org/bloodadvances/…

Congratulations Drs. Heczey and Metelitsa for their publication in Nature Medicine. #Neuroblastoma #CellTherapy bcm.edu/news/car-nkt-c…

GD2-CAR.15 NKTs are safe and can mediate objective responses in patients with NB. Additionally, their anti-tumor activity may be enhanced by targeting BTG1. @BCMCancerCenter @TexasChildrens nature.com/articles/s4159…

FLAG-IDA font line therapy in AML in peda, reduced anthracyclinw exposure in peds.. comprable outcomes onlinelibrary.wiley.com/doi/full/10.11…

Low-dose TBI in mice sensitizes tumor cells to CD19 CART. Timing of CART relative to TBI may be important as effects of radiation, mediated via the death receptor pathway, quickly subside @BloodAdvances #CARTcells @CarlDeSelm doi.org/10.1182/blooda…

We are fortunate that volunteers from all over support our patients. Today, they came from a galaxy far, far away. May the 4th be with you. Discover how you can provide a special event for our kids at stlouischildrens.org/conditions-tre….

Is all T cell failure a result of exhaustion? In this new paper, we demonstrate that chronic stimulation of CARs containing 41BB drives a novel state of T cell dysfunction that is phenotypically, transcriptionally and epigenetically distinct from classical exhaustion.

Blinatumomab added to Interfant-06 backbone improves 2 year DFS in KMT2Ar infant ALL by 30% compared to historical controls. No lineage switch. Amazing results. nejm.org/doi/full/10.10…

Our work on understanding the underlying cause behind failures to expand potent tumor-specific T cells from patients and thereby establishing a clinically feasible approach to overcome it.

Join us in congratulating #WUDeptMedicine Dr. Amanda Cashen, Professor of Medicine in Oncology, on her new position as Associate Chief for Hematopoietic Malignancies. Read more: ow.ly/R0Q850NL8Pl @WUSTLmed @BarnesJewish @WashUOnc